Body-on-a-chip device predicts cancer drug responses
Company 2019
Hesperos Inc., Orlando, USA
Using a body-on-a-chip device, researchers from Hesperos, Inc., circulated blood-like fluid through a multi-chamber chip cultured with tissue types as human heart, liver, bone marrow and cancer cells along with anti-cancer drugs to simultaneously assess efficacy and safety. The system correctly identified known adverse effects and could assess the efficacy of different drugs and drug combinations.
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics
James J. Hickman
Christopher W. McAleer et al. Science Translational Medicine 2019 [1]
Hesperos, Inc. [2]
Physicians Committee for Responsible Medicine [3]
Added on: 05-25-2020
[1] https://stm.sciencemag.org/content/11/497/eaav1386.short
[2] https://hesperosinc.com/hesperos-featured-nih-director-blog/[3] https://www.pcrm.org/news/ethical-science/body-chip-technology-predicts-cancer-therapeutics-reaction
